Physician
Colorado Pain Practice, PLLC
Colorado Pain Practice, PLLC was paid $7.07M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 32% of everything it billed.
33Billing provider infoCOLORADO PAIN PRACTICE, PLLC
LAKEWOOD, CO 80228
LAKEWOOD, CO 80228
33aNPI1508285776assigned 04/15/2014
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$7.07M
24GClaims176,966
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Colorado
Rank by total paid#1 of 30
Median peer was paid$54K
This provider vs. median131×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,619 | $1.07M | |
| 2019 | 29,440 | $1.44M | |
| 2020 | 21,979 | $912K | |
| 2021 | 27,838 | $1.24M | |
| 2022 | 22,413 | $1.09M | |
| 2023 | 22,305 | $1.00M | |
| 2024incomplete | 8,372 | $316K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 43,932 | 35,786 | $2.23M |
| 64635 | 7.6% | 2,426 | 1,688 | $537K | |
| 01936 | 5.5% | 2,637 | 1,963 | $387K | |
| 64633 | 5.4% | 1,518 | 1,134 | $383K | |
| 01992 | 5.0% | 3,643 | 2,690 | $352K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 11,059 | 4,550 | $285K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.6% | 3,628 | 3,038 | $258K |
| 64483 | 3.3% | 2,599 | 1,762 | $233K | |
| 64634 | 3.0% | 1,275 | 942 | $213K | |
| A4550 | Surgical trays | 2.7% | 5,818 | 3,606 | $190K |
| 64636 | 2.5% | 2,209 | 1,459 | $175K | |
| 64484 | 2.4% | 2,493 | 1,696 | $169K |
63 more codes
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.2% | 7,708 | $154K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 10,466 | $137K |
| 76942 | 1.9% | 3,477 | $135K | |
| 64490 | 1.2% | 1,330 | $82K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1.1% | 5,370 | $76K |
| 64493 | 1.0% | 1,252 | $73K | |
| 64640 | <1% | 3,672 | $59K | |
| 64451 | <1% | 379 | $57K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,978 | $56K |
| 01938 | <1% | 612 | $55K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,609 | $48K |
| 80365 | <1% | 4,128 | $46K | |
| 80361 | <1% | 3,365 | $43K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 430 | $42K |
| 80355 | <1% | 3,341 | $42K | |
| 80346 | <1% | 3,095 | $42K | |
| 80373 | <1% | 2,608 | $39K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,076 | $38K |
| 64491 | <1% | 1,301 | $35K | |
| 80362 | <1% | 2,848 | $35K | |
| 99152 | <1% | 2,035 | $35K | |
| 01937 | <1% | 379 | $35K | |
| 64494 | <1% | 1,199 | $32K | |
| 64450 | <1% | 1,998 | $32K | |
| 64625 | <1% | 73 | $29K | |
| 64492 | <1% | 1,045 | $28K | |
| 01991 | <1% | 389 | $25K | |
| 64495 | <1% | 820 | $22K | |
| 97161 | <1% | 347 | $18K | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 7,688 | $17K |
| 20611 | <1% | 551 | $15K | |
| 62321 | <1% | 209 | $12K | |
| 77002 | <1% | 381 | $9K | |
| 27096 | <1% | 176 | $8K | |
| 97162 | <1% | 276 | $7K | |
| 01940 | <1% | 66 | $7K | |
| 81025 | <1% | 1,376 | $6K | |
| 01939 | <1% | 45 | $5K | |
| 20553 | <1% | 316 | $4K | |
| 00300 | <1% | 38 | $4K | |
| 64454 | <1% | 21 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,665 | $1K |
| 80353 | <1% | 63 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $1K |
| 80354 | <1% | 62 | $973.56 | |
| 80324 | <1% | 58 | $910.40 | |
| 64447 | <1% | 38 | $812.97 | |
| 80366 | <1% | 101 | $714.47 | |
| 80348 | <1% | 43 | $666.12 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,584 | $567.44 |
| 20610 | <1% | 13 | $509.27 | |
| 80372 | <1% | 30 | $444.08 | |
| 80359 | <1% | 29 | $427.00 | |
| 80357 | <1% | 29 | $427.00 | |
| 80345 | <1% | 29 | $427.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 243 | $332.99 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 200 | $250.70 |
| 84311 | <1% | 155 | $163.82 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,313 | $108.33 |
| 82570 | <1% | 149 | $40.92 | |
| 83986 | <1% | 151 | $28.32 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 159 | $3.30 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 101 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOGHIM, ROBERT (CEO)
| Provider | Location | Paid |
|---|---|---|
| Colorado Pain Practice, LLC | Denver, CO | $70K |
| Colorado Pain Practice, LLC | Denver, CO | $38K |
| Colorado Pain Practice, LLC | Castle Rock, CO | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.